bupropion associated_with smoking cessation
Evidence from:
primary |
all sources
Evidence (5 sources)
Predictors of relapse in a bupropion trial for smoking cessation in recently-abstinent alcoholics: preliminary results using an aggregate genetic risk score.
(2012)
PMID:23032639
cited
the bupropion literature ... are not available in the bupropion literature ... equivalent effects of each polymorphism on smoking cessation outcome.
confidence: 0.90
Predictors of relapse in a bupropion trial for smoking cessation in recently-abstinent alcoholics: preliminary results using an aggregate genetic risk score.
(2012)
PMID:23032639
cited
Participants were randomly assigned to bupropion ... to participate in a double-blind, placebo-controlled smoking cessation clinical trial.
confidence: 0.96
Predictors of relapse in a bupropion trial for smoking cessation in recently-abstinent alcoholics: preliminary results using an aggregate genetic risk score.
(2012)
PMID:23032639
cited
mixed findings in the smoking cessation literature... a more broadly-based AGRS that included additional variants implicated by bupropion’s pharmacology would have improved the ability of the AGRS to moderate treatment.
confidence: 0.80
Predictors of relapse in a bupropion trial for smoking cessation in recently-abstinent alcoholics: preliminary results using an aggregate genetic risk score.
(2012)
PMID:23032639
cited
The study models the complex genetics of smoking cessation and discusses pharmacogenetic predictors of bupropion response, implying bupropion’s relevance to smoking cessation.
confidence: 0.60
Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.
(2012)
PMID:22290489
cited
FDA-approved approaches for smoking cessation include nicotine replacement therapy (NRT), bupropion, and varenicline.
confidence: 0.95